AOD9604 is a synthetic fragment of human growth hormone designed to influence fat metabolism, whereas GLP1 medications like Semaglutide act on gut and brain hormone pathways to reduce appetite and improve blood sugar
This provides full confidence in producing industry best results for our consumers through strict compliance with cGMP regulations
While large human trials are pending, preclinical and mechanistic evidence is strong
Results can vary widely depending on the individual, their lifestyle habits, overall health, and whether theyre pairing therapy with nutrition, exercise, sleep, and strength training
In Stock Product Specifications Product Overview Key Features Company Details Reticine Pharmaids Limited, a leading marketing & manufacturing Co